Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1I | Q9P0X4 | 4/20 | 0.73 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.73 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
| ▸ | CNR2 | P34972 | 1/20 | 0.66 |
| ▸ | ACACB | O00763 | 15/20 | 0.51 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.41 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1063024 | 1.00 | CACNA1I (0.73) | CACNA1ICACNA1GCACNA1HKCNH2CNR2 | |
| SCHEMBL1061482 | 0.92 | CACNA1I (0.69) | CACNA1ICACNA1GCACNA1HKCNH2CNR2 | |
| SCHEMBL1064133 | 0.89 | CACNA1I (0.60) | CACNA1ICACNA1GCACNA1HKCNH2CNR2 | |
| SCHEMBL12338143 | 0.88 | CACNA1I (0.72) | CACNA1ICACNA1GCACNA1HKCNH2CNR2 | |
| SCHEMBL1064238 | 0.86 | CACNA1I (0.69) | CACNA1ICACNA1GCACNA1HKCNH2CNR2 | |
| SCHEMBL23327963 | 0.84 | CACNA1I (1.00) | CACNA1ICACNA1GCACNA1HKCNH2CNR2 | |
| SCHEMBL8233861 | 0.84 | CACNA1I (1.00) | CACNA1ICACNA1GCACNA1HKCNH2CNR2 | |
| SCHEMBL29363972 | 0.84 | CACNA1I (1.00) | CACNA1ICACNA1GCACNA1HKCNH2CNR2 | |
| SCHEMBL1065470 | 0.82 | CACNA1I (0.67) | CACNA1ICACNA1GCACNA1HKCNH2CNR2 | |
| SCHEMBL1060457 | 0.81 | CACNA1I (0.82) | CACNA1ICACNA1GCACNA1HKCNH2CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2010493-B1 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-27 | — | — | EP | claimed |
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | claimed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | claimed |
| EP-2010493-B1 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-27 | — | — | EP | disclosed |
| EP-2010493-B1 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-01-27 | — | — | EP | disclosed |
| US-8263627-B2 | Pyridyl amide T-type calcium channel antagonists | MERCK SHARP & DOHME CORP. (US) | 2012-09-11 | — | — | US | disclosed |
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-12 | — | — | US | disclosed |
| US-7875636-B2 | 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-7875636-B2 | 2-(4-isopropenylphenyl)-N-[(1R)-1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl]acetamide; epilepsy, pain, neuropathic pain, schizophrenia, Parkinson's disease, depression, anxiety, sleep disorders, psychosis, schizophrenia, cardiac arrhythmia and hypertension | MERCK SHARP & DOHME CORP. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | disclosed |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | MERCK SHARP & DOHME LLC | 2009-11-05 | — | — | US | disclosed |
| WO-2007120729-A2 | PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS | MERCK & CO., INC. (US) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112064-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | CACNA1G, CACNA1H, CACNA1I | CACNA1I 3/4885CACNA1G 1/4885CACNA1H 2/4885 |
| US-20090275550-A1 | Pyridyl Amide T-Type Calcium Channel Antagonists | CACNA1G, CACNA1H, CACNA1I | CACNA1I 3/4885CACNA1G 1/4885CACNA1H 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.